Survival rates in metastatic gastroenteropancreatic neoplasms after multidisciplinary approach

Raluca Trifanescu; Madalina Iftimie; Alexandra Mohora; Iustin Toma; Oana Trifanescu; Catalina Poiana

doi:10.1530/endoabs.94.P50

P50

Prev Next

Section Contents Cite

Endocrine Abstracts (2023) 94 P50 | DOI: 10.1530/endoabs.94.P50

SFEBES2023 Poster Presentations Endocrine Cancer and Late Effects (15 abstracts)

Survival rates in metastatic gastroenteropancreatic neoplasms after multidisciplinary approach

Raluca Trifanescu ^1,2 , Madalina Iftimie ² , Alexandra Mohora ² , Iustin Toma ^1,2 , Oana Trifanescu ^1,3 & Catalina Poiana ^1,2

Err

Author affiliations

¹"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. ²"C.I. Parhon" National Institute of Endocrinology, Bucharest, Romania. ³"Al. Trestioreanu" Institute of Oncology, Bucharest, Romania

Background: Prevalence of neuroendocrine neoplasms is increasing and multidisciplinary approach is mandatory. This study aimed to assess the outcome of patients with gastroenteropancreatic neoplasms (GEP NEN) presenting in a tertiary endocrine center.

Methods: Retrospective study on 36 patients (16 M/20 F) with pathology confirmed GEP NEN, aged 51.9 ± 12.7 years. Serum chromogranin A, serotonin, neuron-specific enolase, NT proBNP, urinary 24h 5 hydroxyindoleacetic acid were measured. Imaging with computed tomography, magnetic resonance were used for staging and assessment of tumour size. Whole-body somatostatin receptor (SSTR) imaging was performed in a subgroup.

Results: Metastatic disease was present in 21 patients (58.3%). Median progression free survival (PFS) was 36 months, with no significant differences between different localizations. Median PFS was not reached for G1 tumors, was 26 months for G2 tumors and 3 months for G3 tumors. Median overall survival was not reached, with 86% of patients’ alieved at 3 years, and 80% of patients’ alieved at 5 years. Tumor size and serotonin levels at diagnosis were significantly higher in patients that will progress later than in patients with no further progression, P= 0.05 and 0.01 respectively.

Conclusions: initial endocrine assessment is helpful in stratifying risk in gastroenteropancreatic tumors and early diagnosis with smaller tumors improved prognosis.